Stock ONVO ORGANOVO HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1 USD +1.20% Intraday chart for Organovo Holdings, Inc. -9.09% -9.91%
Apr. 15 Organovo's fatty liver disease drug meets main goal in mid-stage study RE
Apr. 15 Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo CI

Valuation

Fiscal Period: Marzo 2018 2019 2020 2021 2022 2023
Capitalization 1 114.2 118.5 53.5 68.61 32.73 19.08
Enterprise Value (EV) 1 70.44 82.06 26.15 31.24 6.241 4.883
P/E ratio -3.17 x -4.3 x -2.84 x -3.95 x -2.86 x -1.11 x
Yield - - - - - -
Capitalization / Revenue 24.8 x 38.3 x 24.4 x - 21.8 x 51.6 x
EV / Revenue 15.3 x 26.5 x 11.9 x - 4.16 x 13.2 x
EV / EBITDA -2.07 x -3.12 x -1.69 x -2.24 x -0.55 x -0.28 x
EV / FCF -4.34 x -7.5 x -4.16 x -6.61 x -1.29 x -0.73 x
FCF Yield -23% -13.3% -24% -15.1% -77.3% -138%
Price to Book 2.57 x 3.39 x 2.01 x 2.13 x 1.08 x 1.25 x
Nbr of stocks (in thousands) 5,542 5,975 6,525 7,117 8,706 8,715
Reference price 2 20.60 19.84 8.200 9.640 3.760 2.190
Announcement Date 5/31/18 6/3/19 5/28/20 6/15/21 6/10/22 7/14/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 4.603 3.091 2.196 - 1.5 0.37
EBITDA 1 -34 -26.29 -15.51 -13.98 -11.34 -17.44
EBIT 1 -35.27 -27.27 -15.75 -14.02 -11.48 -17.73
Operating Margin -766.26% -882.37% -717.12% - -765.27% -4,792.16%
Earnings before Tax (EBT) 1 -34.8 -26.63 -18.71 -16.82 -11.45 -17.26
Net income 1 -34.8 -26.64 -18.71 -16.83 -11.45 -17.26
Net margin -756.09% -861.7% -852% - -763.2% -4,664.59%
EPS 2 -6.490 -4.617 -2.888 -2.438 -1.315 -1.981
Free Cash Flow 1 -16.22 -10.94 -6.284 -4.73 -4.826 -6.716
FCF margin -352.3% -353.81% -286.18% - -321.76% -1,815.1%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/31/18 6/3/19 5/28/20 6/15/21 6/10/22 7/14/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q1 2024 Q2 2024 Q3
Net sales 1 - - 0.005
EBITDA - - -
EBIT 1 - -4.115 -3.68
Operating Margin - - -73,600%
Earnings before Tax (EBT) - - -
Net income 1 -4.028 -3.994 -3.604
Net margin - - -72,080%
EPS 2 -0.4600 -0.4600 -0.4000
Dividend per Share - - -
Announcement Date 8/10/23 11/9/23 2/8/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 43.7 36.5 27.4 37.4 26.5 14.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -16.2 -10.9 -6.28 -4.73 -4.83 -6.72
ROE (net income / shareholders' equity) -65.1% -65.9% -59.5% -51.1% -33% -75.8%
ROA (Net income/ Total Assets) -37% -37.7% -28.5% -25.6% -19.6% -41.3%
Assets 1 93.94 70.66 65.64 65.64 58.41 41.75
Book Value Per Share 2 8.030 5.850 4.080 4.520 3.470 1.760
Cash Flow per Share 2 7.880 5.880 4.190 4.310 3.290 1.760
Capex 1 0.23 0.08 - 0.41 0.41 0.4
Capex / Sales 4.91% 2.56% - - 27.27% 107.03%
Announcement Date 5/31/18 6/3/19 5/28/20 6/15/21 6/10/22 7/14/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ORGANOVO HOLDINGS, INC. Stock Organovo Holdings, Inc.
-9.91% 11.39M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ONVO Stock
  4. Financials Organovo Holdings, Inc.